ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

FGFR3

fibroblast growth factor receptor 3 · also CEK2, JTK4, CD333, ACH · CD molecules

9 programs in company-led studies act on FGFR3, from 8 companies: 5 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (9 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
nintedanibruleBoehringer Ingelheiminhibitorphase 4761 runningFGFR1, FGFR2, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRBChEMBL
masitinibruleAB Scienceinhibitorphase 3384 runningKIT, PDGFRA, PDGFRBChEMBL
futibatinibruleOtsukainhibitorphase 3104 runningFGFR1, FGFR2, FGFR4ChEMBL
infigratinibruleBridgeBioinhibitorphase 3173 runningFGFR1, FGFR2, FGFR4ChEMBL
vepugratinibruleEli Lillyinhibitorphase 353 running–NCIt
pemigatinibruleIncyteinhibitorphase 3161 runningFGFR1, FGFR2ChEMBL
dabogratinibruleTyra Biosciencesinhibitorphase 255 running–NCIt
Anti-FGFR3 Antibody-drug Conjugate BHV-1530ruleBiohaven Therapeutics–phase 111 running–NCIt
FGFR3/4 Inhibitor TYRA-430ruleTyra Biosciencesinhibitorphase 111 running–NCIt

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.